Anzeige
Mehr »
Freitag, 04.07.2025 - Börsentäglich über 12.000 News
+210 % Kursgewinn Year to Date: Neuausrichtung nimmt Fahrt auf - jetzt exklusives CEO-Interview ansehen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
279 Leser
Artikel bewerten:
(1)

Brainomix Awarded Prestigious AI Grant to Demonstrate Impact in NHS

Company Selected to Participate in Groundbreaking NHS AI Initiative

OXFORD, England, Sept. 8, 2020 /PRNewswire/ -- Brainomix were announced today as winners of an Artificial Intelligence in Health and Care Award by Secretary of State for Health, Matt Hancock, at the Founders Forum HealthTech Summit in London, which includes a significant grant that will enable Brainomix to deploy its software, the e-Stroke Suite, across a number of UK stroke networks and evaluate its impact on stroke care across these regions. "Today's funding will ensure the NHS can continue to fast-track pioneering artificial intelligence to the frontline, freeing up clinicians' time and saving lives," Hancock said.

Brainomix logo

Organised by the Accelerated Access Collaborative (AAC) in partnership with NHSX and the National Institute for Health Research (NIHR), the awards are designed to accelerate the testing and evaluation of the most promising AI technologies which meet the strategic aims set out in the NHS Long Term Plan. "The NHS has and always will rely first and foremost on the clinical expertise of our staff, but the innovations we're funding today have the potential to save lives by improving screening, cancer treatment and stroke care for NHS patients across the country," noted Sir Simon Stevens, NHS Chief Executive.

"We are delighted and honoured to be selected for this prestigious award, from a group of nearly 500 other applicants. As an Oxford-based company, we are proud of our UK heritage and excited to be part of this innovative programme - one which promises to accelerate the pace of AI adoption in healthcare, while also helping the NHS deliver improved care through transformative solutions," noted Dr Michalis Papadakis, CEO and co-founder of Brainomix.

The e-Stroke Suite supports both specialist and non-specialist clinicians to interpret stroke brain scans in real-time, and to identify patients who need urgent treatments or transfer to a specialist hospital. Using the e-Stroke mobile app, doctors can then securely share brain scans with specialists at other hospitals, bringing expert decision making to all hospital Emergency Departments 24/7.

"Earlier this year the e-Stroke Suite was successfully deployed at the Royal Berkshire Hospital in Reading, and with this grant, we now have an opportunity to evaluate the e-Stroke Suite across multiple NHS networks. We are looking forward to partnering with the NHS, both locally and nationally, to measure the opportunity for Brainomix AI technology to improve patient care in all hospitals. We are excited to help unlock access to time-critical stroke treatments (such as thrombolysis and mechanical thrombectomy) for more patients, by empowering frontline NHS clinicians to make more confident and faster decisions," explained Dr George Harston, Chief Medical & Innovation Officer at Brainomix.

Brainomix is a partner of the National Consortium of Intelligent Medical Imaging (NCIMI), a strategic network of NHS hospitals, clinical leaders, industry experts, world-leading researchers, plus patient groups and charities - all focused on driving innovation in the UK's AI sector. Its CEO, Dr Claire Bloomfield, said: "This is incredible news for our partner Brainomix and will help further the reach of the e-Stroke Suite deployment; assessing impact for patients across the UK. At NCIMI we're very pleased that the work we have done with Brainomix can be further expanded across the UK. Having seen the benefits of the adoption of this AI with our NHS Trusts in NCIMI (for example with Royal Berkshire), it is great news that this can have greater reach through the support from NHSX. Expanding this evaluation work will provide vital evidence and create a national picture for the effective use of AI tech in healthcare."

About Brainomix

Brainomix is an Oxford-based company specializing in the creation of AI-powered software solutions to unlock the potential of life-saving treatments. Founded in 2010 as an offshoot of the University of Oxford, its e-Stroke Suite provides clinicians with the most comprehensive stroke imaging solution, helping to interpret images and facilitating faster, more confident treatment decisions for patients with suspected stroke. To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on Twitter, Facebook and LinkedIn.

Logo - https://mma.prnewswire.com/media/1009142/Brainomix_Logo.jpg

© 2020 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.